ImmuneOnco Biopharmaceuticals (IOB HK) Pre-IPO: A Potentially Differentiated Oncology Portfolio
323 Views03 Aug 2022 23:28
SUMMARY
- ImmuneOnco Biopharmaceuticals (Shanghai) (IOB HK) has a differentiated next-generation immuno-oncology pipeline targeting a wide range of solid and hematologic tumors to address critical unmet medical needs.
- The company's lead candidate IMM01 is being developed for the treatment of various hematologic malignancies and solid tumors as monotherapy and in combination with other agents.
- The company has already undertaken a series of fund raising. Its current cash position can fund its operating expenses for more than two years, without the IPO proceeds.
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
x